12:00 AM
May 06, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Asunaprevir/daclatasvir/BMS-791325 regulatory update

Bristol-Myers Squibb disclosed in its 1Q13 earnings that FDA granted breakthrough therapy designation for the fixed-dose combination of asunaprevir, daclatasvir and BMS-791325 to treat chronic...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >